ClinicalTrials.gg

Program

Meloxicam

Also written as “HTX-011”, “N1539” and “Meloxicam tablet”.

Its studies are mostly in Pain, Postoperative · Osteoarthritis · Arthritis, Rheumatoid · Hernia, Inguinal · Pain, led by 16 companies.

Furthest: phase 4, since Jul 4, 201466 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim220 open or runningphase 4since Jul 4, 2014May 2, 2002none ahead
Heron Therapeutics161 open or runningphase 4since Oct 1, 2021Jun 9, 2015none ahead
Baudax Bio70 open or runningphase 4since Mar 15, 2022Aug 31, 2015none ahead
Alkermes30 open or runningphase 3since Sep 15, 2011Jul 23, 2009none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jul 12, 2010Jul 12, 2010none ahead
Eurofarma Laboratorios20 open or runningphase 3since Apr 24, 2012Apr 24, 2012none ahead
Grünenthal20 open or runningphase 3since Sep 22, 2014Mar 18, 2013none ahead
Hikma Pharmaceuticals20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Feb 6, 2009Feb 6, 2009none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
GlaxoSmithKline10 open or runningno phasesince Nov 28, 2012Nov 28, 2012none ahead
joint-stock-company-farmak10 open or runningphase 1since Nov 15, 2021Nov 15, 2021none ahead
Pfizer10 open or runningno phasesince Sep 6, 2011Sep 6, 2011none ahead
Sino Biopharmaceutical11 open or runningphase 2since Jul 10, 2023Jul 10, 2023none ahead
yangtze-river-pharmaceutical-group-co-ltd10 open or runningphase 3since Mar 25, 2025Mar 25, 2025none ahead
zodiac-produtos-farmaceuticos-s-a10 open or runningphase 3since May 11, 2015May 11, 2015none ahead

Also a collaborator on its studies: eurotrials-brasil-consultores-cientificos-ltda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Jan 15, 2008.

  1. Sep 24, 2018Phase 1 study in HealthyBoehringer Ingelheim · NCT03684265 · 26 enrolled · Russian Federation
  2. Oct 1, 20182 phase 2 studies in Pain, PostoperativeHeron Therapeutics · NCT03695367, NCT03718039
  3. Apr 5, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03907176 · 209 enrolled · United States
  4. Apr 17, 2019Phase 2 study in AgnosiaHeron Therapeutics · NCT03922048
  5. Apr 29, 2019Phase 3 study in Osteoarthritis, KneeEurofarma Laboratorios · NCT03936192
  6. May 9, 2019Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT03955211 · 25 enrolled · United States
  7. Jun 3, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03974932 · 116 enrolled · United States
  8. May 27, 2021Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT04911062 · 32 enrolled · United States
  9. Oct 1, 2021Phase 4 study in AgnosiaHeron Therapeutics · NCT05109312 · 90 enrolled · United States
  10. Nov 15, 2021joint-stock-company-farmak's first study: phase 1 study in PharmacokineticsNew to joint-stock-company-farmakjoint-stock-company-farmak · NCT05125588 · 24 enrolled
  11. Mar 15, 2022Phase 4 study in Pain, PostoperativeBaudax Bio · NCT05315479 · 19 enrolled · United States
  12. Jul 10, 2023Sino Biopharmaceutical's first study: phase 2 study in Pain, PostoperativeNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05950152 · 108 planned · China
  13. Oct 25, 20232 phase 4 studies in Pain, PostoperativeHeron Therapeutics · NCT06109428, NCT06109415
  14. Mar 25, 2025yangtze-river-pharmaceutical-group-co-ltd's first study: phase 3 study in Participants With Acute Moderate to Severe Pain Following Abdominal SurgeryNew to yangtze-river-pharmaceutical-group-co-ltdyangtze-river-pharmaceutical-group-co-ltd · NCT06904248 · 224 enrolled · China

TargetBeta

PTGS2 →read by rule
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule

Other programs on PTGS2

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
CelecoxibruleViatrisphase 478
EtoricoxibruleOrganonphase 435
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06904248Participants With Acute Moderate to Severe Pain Following Abdominal Surgery · China3Completedyangtze-river-pharmaceutical-group-co-ltdNov 20, 2024224
NCT06109428Pain, Postoperative · United States4CompletedHeron TherapeuticsMar 29, 202237
NCT06109415Pain, Postoperative · United States4CompletedHeron TherapeuticsJul 18, 202230
NCT05950152Pain, Postoperative · China2Not yet recruitingSino BiopharmaceuticalDec 2023108
NCT05315479Pain, Postoperative · United States4TerminatedBaudax BioJul 7, 202219
NCT05125588Pharmacokinetics1Completedjoint-stock-company-farmakFeb 26, 201424
NCT05109312Agnosia · United States4Active, not recruitingHeron TherapeuticsJun 202490
NCT04911062Pain, Postoperative · United States2CompletedHeron TherapeuticsJul 29, 202232
NCT03974932Agnosia · United States3CompletedHeron TherapeuticsDec 7, 2020116
NCT03955211Pain, Postoperative · United States2CompletedHeron TherapeuticsDec 3, 202125
NCT03936192Osteoarthritis, Knee3WithdrawnEurofarma LaboratoriosFeb 20210
NCT03922048Agnosia2WithdrawnHeron TherapeuticsNov 20250
NCT03907176Agnosia · United States3CompletedHeron TherapeuticsOct 25, 2021209
NCT03718039Pain, Postoperative · United States2CompletedHeron TherapeuticsJan 31, 201978
NCT03695367Pain, Postoperative · United States2CompletedHeron TherapeuticsNov 20, 201863
NCT03684265Healthy · Russian Federation1CompletedBoehringer IngelheimOct 30, 201826
NCT03434275Pain, Postoperative · United States3CompletedBaudax BioMay 21, 2019194
NCT03323385Pain, Postoperative · United States3CompletedBaudax BioSep 26, 201857
NCT03295721Pain, Postoperative · United States3CompletedHeron TherapeuticsJan 8, 2018412
NCT03237481Pain, Postoperative · United States, Belgium3CompletedHeron TherapeuticsDec 22, 2017418
NCT03015532Pain, Postoperative · United States2CompletedHeron TherapeuticsApr 20, 2018285
NCT03011333Pain, Postoperative · United States2CompletedHeron TherapeuticsFeb 1, 2018243
NCT02720692Pain, Postoperative · United States, Australia, Canada and more3CompletedBaudax BioMar 2017722
NCT02678286Pain, Postoperative · United States3CompletedBaudax BioOct 2016219
NCT02675907Pain, Postoperative · United States3CompletedBaudax BioJul 2016201
NCT02540265Pain, Postoperative · United States2CompletedBaudax BioNov 201559
NCT02504580Pain, Postoperative · United States2CompletedHeron TherapeuticsMar 2017463
NCT02471898Agnosia · United States2CompletedHeron TherapeuticsSep 201571
NCT02448199Osteoarthritis3UNKNOWNzodiac-produtos-farmaceuticos-s-aJun 2016375
NCT02255045Dysmenorrhea · Chile3CompletedGrünenthalFeb 21, 201668
NCT02229747Pharyngitis4CompletedBoehringer IngelheimFeb 2002128
NCT02187575Healthy1CompletedBoehringer IngelheimSep 200226
NCT02187562Healthy1CompletedBoehringer IngelheimAug 200216
NCT02183181Healthy1CompletedBoehringer IngelheimJan 20096
NCT02183168Spondylitis, Ankylosing3CompletedBoehringer IngelheimMay 1, 2002192
NCT02183129Osteoarthritis4CompletedBoehringer IngelheimNov 1, 199991
NCT02183116Osteoarthritis4CompletedBoehringer IngelheimFeb 199930
NCT02183077Healthy1CompletedBoehringer IngelheimNov 199812
NCT02183064Osteoarthritis3CompletedBoehringer IngelheimNov 20001,309
NCT02183051Pain2CompletedBoehringer IngelheimOct 1998381
NCT02183025Dysmenorrhea2CompletedBoehringer IngelheimApr 1999337
NCT02181907Healthy1CompletedBoehringer IngelheimApr 200322
NCT02181322Healthy1CompletedBoehringer IngelheimSep 200124
NCT02181309Healthy1CompletedBoehringer IngelheimApr 200224
NCT02180490Healthy1CompletedBoehringer IngelheimJul 200260
NCT02180477Healthy1CompletedBoehringer IngelheimDec 20019
NCT01839643Contraception · Chile1CompletedGrünenthalMay 7, 201313
NCT01750931Arthritis, Rheumatoid–CompletedGlaxoSmithKlineOct 1, 201328
NCT01587508Acute Lumbago · Brazil3WithdrawnEurofarma LaboratoriosMay 20130
NCT01436032Laparoscopic Surgery · United States3TerminatedAlkermesMar 201250
NCT01430559Osteoarthritis, Knee · China–CompletedPfizerMar 27, 2013408
NCT01161147Healthy · Canada1CompletedDr. Reddy's LaboratoriesDec 200428
NCT01161134Healthy · Canada1CompletedDr. Reddy's LaboratoriesNov 200428
NCT01084161Hysterectomy · Georgia, Poland, Serbia2CompletedAlkermesJan 2011486
NCT00945763Toothache · United States2CompletedAlkermesNov 2009230
NCT00840879Healthy · Canada1CompletedTeva Pharmaceutical IndustriesFeb 200428
NCT00840476Healthy · Canada1CompletedTeva Pharmaceutical IndustriesFeb 200428
NCT00649675Healthy · United States1CompletedViatrisSep 200427
NCT00649077Healthy · United States1CompletedViatrisSep 200430
NCT00618163Inflammation · United States–CompletedHikma PharmaceuticalsApr 200547

How it is read

Names in the registry

  • “HTX-011”, 20 entries
  • “N1539”, 18 entries
  • “Meloxicam”, 12 entries
  • “Meloxicam tablet”, 3 entries
  • “Meloxicam 15 mg Tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.